Table 4.
Total Mean Number of Supplied Drugs During the 5 Years Prior to OSA Diagnosis
| Women (n=289) |
Men (n=289) |
|||||
|---|---|---|---|---|---|---|
| Parameter | Mean number of supplied drugs±SEM of OSA patients (Median, range) | Mean Difference ±SEM | P value | Mean number of supplied drugs±SEM of OSA patients (Median, range) | Mean Difference ±SEM | P value |
| Cardiovascular system (C) | 25.7±2.7 (2, 0–253) | 6.7±3.1 | 0.096 | 31.8±2.7 7 (0–308) | 15.9±3.3 | <0.0001 |
| Respiratory system (R) | 13.5±1.1# (8, 0–159) | 5.7±1.4 | <0.0001 | 8.8±0.8 (5, 0–110) | 2.4±1.8 | <0.0001 |
| Analgestics (N02) | 9.3±0.8# (4, 0–87) | 2.0±1 | 0.004 | 5.6±0.5 (2, 0–54) | 2.1±0.7 | <0.0001 |
| Antibacterials for systemic Use (J01) | 7.2±0.4# (5, 0–50) | 1.9±0.5 | <0.0001 | 4.5±0.3 (3, 0–41) | 1.7±0.4 | <0.0001 |
| Psycholeptics and psychoanaleptics (N05, N06) | 7.6±1.1# (1, 0–228) | 2.7±1.4 | <0.0001 | 3.8±0.6 (0, 0–94) | 1.2±0.8 | <0.0001 |
| Anti-inflammatory and anti-rheumatic products (M01) | 5.8±0.5# (3, 0–50) | 1.5±0.6 | 0.002 | 3.6±0.4 (2, 0–62) | 2.1±0.4 | <0.0001 |
| Peptic ulcer and gastroesophageal reflux disease (A02B) | 4.5±0.6* (1, 0–69) | 1.7±0.7 | 0.001 | 3.3±0.5 (0, 0–62) | 1.6±0.6 | 0.001 |
| Vitamins (A08, A11) | 4.3±0.6# (1, 0–96) | 1.7±0.7 | 0.002 | 1.5±0.3 (0, 0–42) | 0.04±0.4 | 0.134 |
Supplied medications are the mean ± SEM (median, range) number of drugs per patient per 5 years. Presented are all pharmacological groups in which differences were found (Difference − mean difference between cases and controls in the number of times per five years the drug was prescribed).
Cardiovascular categories include: Therapy and Selective Calcium Channel Blockers with Direct Cardiac Effect (C01, C08D); Antiadrenergic Agents, Centrally Acting and Antiadrenergic Agents, Peripherally Acting (C02A,C02C); Arteriolar Smooth Muscle, Agents Acting On (C02D); Low Ceiling Diuretics, Thiazides and Low Ceiling Diuretics, Excluding Thiazides and Potassium Sparing Agents and Diuretics and Potassium Sparing Agents in Combination (C03A, C03B,C03D, C03E); High Ceiling Diuretics (C03C); Peripheral Vasodilators (C04); Vasoprotectives (C05); Beta Blocking Agents (C07); Selective Calcium Channel Blockers with Mainly Vascular Effects (C08C); ACE-Inhibitors, Plain and ACE-Inhibitors, Combinations (C09A,C09B); Angiotensin II Antagonists and Angiotensin II Antagonists, Combinations (C09C,C09D); Cholesterol and Triglyceride Reducers (C10A).
Cardiovascular system drugs was analyzed according to methods described by Otake et al.25 Comparison between OSA patients and controls was performed by Wilcoxon test. Comparison between women and men OSA patients was performed by Mann-Whitney test (*P < 0.05, #P < 0.0001). P value comparing OSA patients to their paired matched controls.